secwatch.observer — SEC 8-K summary
======================================

Issuer:     HERON THERAPEUTICS, INC. /DE/ (HRTX)
CIK:        0000818033
Form:       8-K
Filed at:   2023-03-13T23:59:59+00:00
Accession:  0000950170-23-007473
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CMS grants pass-through payment status for Heron's APONVIE effective April 1, 2023
--------------------------------------------------------------------------------

- CMS approves three-year transitional pass-through status for APONVIE under C-code C9145 starting April 1, 2023.
- APONVIE will be reimbursed separately outside surgical bundle at ASP+6% in HOPD and ASC settings.
- APONVIE is the only PONV drug with Medicare reimbursement in both outpatient settings; launched March 6, 2023.
- Over 70% of surgery opportunity is in outpatient settings; CEO says status facilitates patient access and billing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/818033/000095017023007473/0000950170-23-007473-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/818033/000095017023007473/hrtx-20230313.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-007473

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer